Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 39UNKNOWN 5INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 1

Interventions

Cisplatin 48Capecitabine 41Gemcitabine 33apatinib 32Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Nivolumab 17pembrolizumab 16Surgical Procedures, Operative 16Exercise 16Metformin 15S 1 (combination) 14camrelizumab 13Radiation 13Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11Vinorelbine 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × nedaplatin × Clear all
NCT07046221 2025-07-20

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Fujian Cancer Hospital

Phase 2 Not yet recruiting
60 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡